TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06696768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06725602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TQ - Proximal Application (high and tight)
Description: Tourniquet application: proximal (high and tight) on arms and thighs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TQ - Proximal Application (high and tight)
Description: Tourniquet application: proximal (high and tight) on arms and thighs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TQ - Proximal Application (high and tight)
Description: Tourniquet application: proximal (high and tight) on arms and thighs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TQ - Controlled application (2-3 inches)
Description: TQ Application: controlled (2-3 inches proximal to the injury) on forearms and legs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TQ - Controlled application (2-3 inches)
Description: TQ Application: controlled (2-3 inches proximal to the injury) on forearms and legs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TQ - Controlled application (2-3 inches)
Description: TQ Application: controlled (2-3 inches proximal to the injury) on forearms and legs.
Study: NCT06726863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport IRF
Description: Vamifeport IRF will be administered orally as per the dosing levels and formulations for respective treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR1
Description: Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR1
Description: Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR1
Description: Vamifeport PR1 will be administered orally as per the dosing levels and formulations for respective treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR2
Description: Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR2
Description: Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamifeport PR2
Description: Vamifeport PR2 will be administered orally as per the dosing levels and formulations for respective treatment periods.
Study: NCT06745531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-172 20~60 mg/day
Description: oral administration of TS-172 20\~60 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo
Study: NCT06751290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling
Description: This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.
Study: NCT06763991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage connection
Description: Two-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear during the second stage surgery of ear reconstruction. An intact cartilage framework is embedded in skin pocket in the first stage, hence, in the second stage of surgery, parts of the cartilage framework that has already survived will be shaved off to ensure the firm combination between the residual era cartilage and grafted costal cartilage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage connection
Description: One-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear in the first stage surgery of ear reconstruction. In one-stage surgery, the cartilage framework is connected with the residual ear (non-deformed, unexcluded part) to form a smooth and complete ear subunit structure. In this way, it is necessary to trim the excess postauricular skin, which may pose a greater risk of blood supply. After the first stage of surgery, the overall appearance of surgical ear is already roughly similar to that of a normal ear.
Study: NCT06767774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: * pitavastatin 4mg~* ezetimibe 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High intensity statin monotherapy
Description: rosuvastatin 20mg
Study: NCT06768541

Intervention type: PROCEDURE
Intervention: THA using a short stem
Description: Total Hip Arthroplasty using a collarless, triple-tapered cementless short stem (Optimys, produced by Mathys).
Study: NCT06761651

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic

Intervention type: DRUG
Group type: OTHER
Intervention: TAVO412
Description: Biologic
Study: NCT05198297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Minimally invasive glaucoma surgery device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic surgery
Description: Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
Study: NCT05582707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
Study: NCT04822896

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinesthetic Motor Imagery Exercises
Description: Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Motor Imagery Exercises
Description: Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets.
Study: NCT06080178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine (static group)
Description: When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-lyte (dynamic group)
Description: Plasmalyte will be administered intravenously:~(1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (dynamic group)
Description: When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min).~When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg.
Study: NCT06260774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-MC138
Description: The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-MC138
Description: The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-MC138
Description: The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.
Study: NCT04339751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Administration of Vorinostat
Study: NCT06283758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focused power ultrasound mediate inferior perirenal adipose tissue modification
Description: This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: focused power ultrasound mediate inferior perirenal adipose tissue modification
Description: This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-control group
Description: Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
Study: NCT06392386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous injections
Study: NCT06384898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Tai Chi
Description: Tai Chi mind-body exercise is a complex, multi-component nonpharmacological intervention integrating physical, psychological, emotional, and behavioral elements.
Study: NCT06768450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mindfulness meditation
Description: The mindfulness meditation program is adapted from the Breathwork Mindfulness for Stress program. However, it uses shorter meditations designed for individuals who cannot sit for 40 minutes. The mindfulness meditation program encourages greater self-acceptance, kindness, and compassion toward oneself. It builds on this concept by helping participants find pleasure in life despite suffering, fostering kindness and compassion toward others, and increasing social connections to counteract the social isolation common among individuals with chronic and long-term illnesses.~The program will be led by a well-trained Breathwork mindfulness instructor and conducted remotely via Microsoft Teams once a week for 8 weeks. Each session will last 2 to 2.5 hours and consist of body scans, mindful movements, and various meditations, introducing new ideas every week.
Study: NCT05517980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
Study: NCT06776679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BGB-16673
Description: Administered orally as suspension in lipid vehicle
Study: NCT06768918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote physical rehabilitation
Description: In this multisite international study, we feasibility test implementation of 4 different digital solutions for delivering interactive physical rehabilitation during or after systemic anticancer treatment. The contents of the intervention follows international recommendations for exercise during or after treatment for cancer.
Study: NCT06778408

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hybrid Palliative Radiation Therapy
Description: Hybrid Palliative Radiation Therapy will be administered to all patients.
Study: NCT06779214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic_L
Description: subject will receive a low-dosage (1\*10\^5) of Bifidobacterium. animalis subsp.Lactis A6 Strain

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol_L
Description: subject will receive a low-dosage (300mg/d) of resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic_M
Description: subject will receive a medium-dosage (1\*10\^8) of Bifidobacterium. animalis subsp.Lactis A6 Strain

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic_H
Description: subjects will receive a high-dosage (1\*10\^10) of Bifidobacterium. animalis subsp.Lactis A6 Strain

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol_H
Description: subject will receive a low-dosage (600mg/d) of resveratrol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo_Bif
Description: subjects will receive placebo (one look-alike sunbstance that contains no prebiotics)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo_resveratrol
Description: subjects will receive placebo (one look-alike sunbstance that contains no resveratrol)
Study: NCT06778889

Intervention type: BEHAVIORAL
Intervention: Undergraduate Medical Students
Description: This is an observational study without any intervention. Data will be collected using standardized questionnaires to assess physical activity, mental health, and stress levels in the participants.
Study: NCT05787899

Intervention type: OTHER
Intervention: Hypothermia Protocol
Description: Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
Study: NCT06296199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music only
Description: The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music.
Study: NCT04450706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precision Medicine
Description: The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physican Decision Making
Description: The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy.
Study: NCT04603495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib
Description: Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
Study: NCT06090539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986458
Description: Specified dose on specified days.
Study: NCT05031026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion rule in prevention of IRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine infusion rule in prevention of IRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: normal saline infusion as a placebo